Medtech’s New Era of System Selling

For most medtech leaders, the challenges of reshaping commercial strategy are well documented. Accelerating Integrated Delivery Network (IDN) consolidation, sustained margin pressure, and increasingly complex enterprise decision-making have reduced the effectiveness of traditional, product-level selling models. As a result, the “national accounts” role in medtech enterprises is evolving. 

Health systems rarely buy devices in isolation anymore. Instead, they evaluate partners based on portfolio alignment, economic impact, and operational dependability across increasingly complex care environments. As a result, national accounts has re-emerged as a strategic lever for enterprise growth, rather than a downstream contracting role. In today’s environment, much of that growth is won or lost at the system level.

Health Systems in 2026: How to Adapt to Evolving IDN Behavior

IDNs continue to expand through mergers, outpatient acquisitions, regional alliances, and aggregation models that now extend far beyond the acute care hospital. With this growth, decision-making has become increasingly distributed across service line leaders, finance, supply chain, and value-analysis committees (though this is dependent on product category and site of care). Product acquisition decisions rarely occur in isolation, but they are not always centralized within the health system.

National accounts leaders are responding to this shift by moving beyond access-driven selling toward a more deliberate, influence-based approach. Instead of focusing on a single executive relationship or periodic stakeholder mapping, they’re developing a better understanding of how decisions are made across service lines, care settings, and economic versus clinical stakeholders. The goal is to understand each health system’s true priorities and align your portfolio accordingly.

Vendor Rationalization Without a Race to the Bottom

More effective teams take a selective approach by explicitly defining where portfolio bundling creates value and where it doesn’t. In practice, this means:

• Treating service-line-critical categories differently from commoditized, transactional segments
• Being disciplined about when portfolio leverage strengthens the value story and when it dilutes it
• Avoiding “all-or-nothing” contracts that undermine long-term credibility

In some situations, avoiding an all-or-nothing contract preserves credibility and positions the organization for a longer-term partnership, rather than short-term price concessions.

From product launches to M&A and manufacturing trends, the MPO Source delivers the medtech news you need twice a week. Subscribe here!

Site-of-Service Shifts are Redefining the Enterprise Ecosystem

The constant migration of procedures to lower-cost sites of care, such as hospital outpatient departments (HOPDs), ambulatory surgery centers (ASCs), and office-based labs (OBLs) has radically changed how enterprise accounts must be managed. These sites introduce fragmented ownership structures, unique economic models, and continually evolving reimbursement dynamics. Pricing and reimbursement are, in many cases, still lagging behind clinical migration, which creates both opportunity and risk for medtech companies.

National accounts leaders are adjusting by segmenting enterprise customers by care-setting strategy rather than IDN affiliation alone. ASC growth demands:

• Different value narratives 
• Different coverage and support models 
• Different expectations of scale and utilization 

As pricing pressure increases over time, these shifts also open the door to lower-cost competitors in the market. What was once a singular enterprise relationship has become a complex ecosystem of interconnected, yet economically distinct, entities.

Portfolio Strategy: Leverage Breadth as a Competitive Advantage

As health systems evaluate vendors at the service-line level, portfolio breadth has become a “defensive” moat against commoditization. More than ever, partners are assessed on their ability to support entire service lines and expand share of wallet across related categories, not just on individual product performance.

Effective teams anchor portfolio discussions around service-line outcomes, not just product counts. Portfolio breadth is used to simplify operations, improve consistency, and reduce variation, not solely as a pricing lever. When portfolio strategy mirrors how health systems manage care delivery, it becomes a source of differentiation rather than internal friction.

That friction remains a real challenge in many large medtech organizations. Multiple business units, competing incentives, disconnected data, and misaligned success metrics can undermine enterprise strategy. As a result, national accounts leaders increasingly serve as economic integrators, balancing portfolio-level objectives with individual P&L priorities while translating enterprise goals across franchises.

How IDNs and GPOs Evaluate Partners Today

Despite the persistent focus on price, health systems don’t select partners based on unit cost alone. Value is measured through total cost of ownership, reliability, service levels, workflow impact, consistent contract execution, and patient outcomes. Price is table stakes, but it’s not always the sole differentiator.

National accounts leaders must reflect this reality by broadening the value conversation and framing price as one lever among many. They lead with total cost of care, execution risk, and operating efficiency. These are areas where health systems are acutely sensitive as margins remain under pressure.

This perspective should also affect how teams approach group purchasing organization (GPO) strategy. GPO influence differs considerably by category. In highly standardized segments, GPOs play a central role. In differentiated or physician-preference categories, GPO contracts often function primarily as access mechanisms. Treating GPO participation as a deliberate, strategic choice, rather than a default approach, has become increasingly important.

Don’t Overlook Contract Performance After the Signature Ink is Dry

Winning the contract does not guarantee commercial success. Most agreements demand share lifts, portfolio pull-through, and behavior change in the field. Without early visibility into contract performance, revenue leakage is all too common.

High-performing organizations treat contract execution as a defined discipline. Clear success metrics are defined before the contract is signed, and performance is reviewed regularly, with visibility shared across national, regional, and field leadership.

In too many companies, negotiation still receives the bulk of the attention while contract execution and performance are left to diffuse ownership and, as a result, inconsistent follow-through. Experienced national accounts leaders understand that the contract is the starting point, not the finish line.

Solving the Problem with Data: More Isn’t Always Better

The problem for most national accounts teams isn’t a lack of data, but a lack of alignment around it. Conflicting internal sources, outdated reporting, and disputed baselines slow decision-making and weaken credibility. 

Instead of chasing more data, enterprise-ready organizations focus on trust, governance, and alignment. They invest in a high-quality, decision-ready view of spend, share, and volume trends that are clearly defined and consistently applied across enterprise, regional, and field teams, allowing decisions to move faster without sacrificing rigor.

Equally important is translating enterprise insights and strategy into frontline action. Without mechanisms to push insights to regional and district levels, enterprise strategy remains disconnected from execution. Regular checkpoints and role-specific performance indicators help span that gap.

What Enterprise-Ready MedTech Organizations Will Look Like in 2026 and Beyond

As cost pressures continue to shrink field forces, enterprise-ready medtech organizations will have to rely on stronger system-level intelligence, cross-franchise and economically aware portfolio planning, and greater cost-effectiveness in how resources are deployed. National accounts leaders will increasingly serve as strategic integrators and internal translators, aligning enterprise objectives with execution in the field.

In an era of consolidation, the medtech companies best positioned to grow will be those that evolve how they sell, not just what they sell, and align their organizations around winning at the system level.